Firebrick Pharma Limited ( (AU:FRE) ) has issued an announcement.
Firebrick Pharma Limited has issued 189,000 ordinary fully paid shares following the exercise of unlisted options at a price of $0.01 per share. This issuance was conducted without disclosure to investors under the Corporations Act, and the company confirms compliance with relevant provisions, ensuring transparency and adherence to regulatory standards.
More about Firebrick Pharma Limited
Firebrick Pharma is a pharmaceutical innovator focused on developing and commercializing novel formulations of povidone-iodine (PVP-I). The company is currently commercializing Nasodine Nasal Spray and has expanded its market presence to the United States, Singapore, Fiji, the South Pacific, and the Philippines.
YTD Price Performance: 50.0%
Average Trading Volume: 201,606
Technical Sentiment Signal: Sell
For detailed information about FRE stock, go to TipRanks’ Stock Analysis page.